International Journal of Oncology · 2003 · 10 citations · 0 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaSurgical OncologyBasal Cell CarcinomaCancer BiomarkersCancer Molecular PathologyMalignant NeoplasmsSquamous Cell CarcinomaTelomere BiologyInfiltrative Basal Cell CarcinomaPrognostic BiomarkersSurgical Margin EvaluationSurgical Resection MarginsTelomerase ActivationTelomerase Activity AssessmentTelomerase EnzymeTelomerase Function
To distinguish the infiltrative from the non-infiltrative basal cell carcinoma (BCC), cell cycle markers are being used to supplement histopathological assessment, and proliferation markers are proving particularly useful. A successful radical therapeutic intervention depends on a clear histopathological diagnosis, especially for the tumour margins. For this purpose we investigated whether proof of telomerase activation is a suitable adjunctive molecular marker. We were also interested in the telomerase activity (TA) of BCC-free margin tissues as a prognostic parameter of relapse. Using PCR-ELISA kits, we found TA in 26/30 (87%) BCC tissues and in 8/25 (32%) of the tumour-free surgical margin tissues. Telomerase levels and the incidence of telomerase-positive tumour tissues are not always associated with positive p53 immunoreactive scores in BCC tissues. But telomerase levels correlate significantly with p53 expression levels. In the Kaplan-Meier curve, patients with telomerase-positive tumour-free surgical margin tissues showed significantly shorter relapse-free periods than patients with telomerase-negative tumour-free margin tissues.